A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Mardepodect (Primary)
- Indications Huntington's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 12 Oct 2016 Status changed from recruiting to completed.
- 27 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 10 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.